RHHBY is all set to acquire Poseida Therapeutics, Inc. and ramp up its pipeline with off-the-shelf cell therapies.
Net profit was 78.1 million zlotys ($18.97 million), which still beat analyst expectations of 73 million zlotys. Revenue for ...